Verici Dx plc (LON:VRCI), a developer of advanced clinical diagnostics for organ transplant, has announced that further to the Company’s announcement earlier today, it has successfully concluded the Bookbuild for its Placing to raise gross proceeds of approximately £2.5 million (before expenses), through the placing of 700,000,000 Placing Shares with existing and new investors at the Issue Price of 0.35 pence. 29 per cent. of the Placing Shares are intended to be EIS/VCT qualifying.
The 700,000,000 Placing Shares represent approximately 46 per cent. of the existing issued share capital of the Company.
Singer Capital Markets and Oberon Capital are acting as placing agents for and on behalf of the Company in respect of the Placing.
A general meeting will be held to obtain allotment and disapplication of pre-emption rights authorities to enable the Directors to issue and allot new Ordinary Shares for cash pursuant to the Fundraising on a non-pre-emptive basis.
Admission
Application will be made to the London Stock Exchange for admission of the Placing Shares to be issued in connection with the Fundraising. It is expected that admission of the Placing Shares will become effective and that dealings in all of the New Ordinary Shares to be issued pursuant to the Fundraising will commence at 8.00 a.m. on 23 June 2026.
The Placing Shares, when issued, will be fully paid and will rank pari passu in all respects with each other and with the existing Ordinary Shares of the Company, including, without limitation, the right to receive all dividends and other distributions declared, made or paid after the date of issue.
Retail Offer
As previously indicated, a Retail Offer is proposed to be launched via the WRAP Platform to provide existing retail investors with an opportunity to take part in the Fundraising at the same Issue Price as the Placing. Further details about the Retail Offer will be provided by the Company by separate announcement in due course.
Related Party Transactions – AIM Rule 13 Disclosures
Further to the announcement released by the Company at 11.40 a.m. on 5 June 2026, Harwood Capital LLP has confirmed its conditional participation in the Placing and will invest in 85,714,287 Placing Shares for consideration of £300,000 at the Issue Price. Immediately prior to this announcement, Harwood Capital owned 188,005,843 Ordinary Shares, representing approximately 12.4 per cent. of the Company’s existing issued ordinary share capital. As a Substantial Shareholder (as defined in the AIM Rules), the participation of Harwood Capital in the Placing constitutes a related party transaction pursuant to Rule 13 of the AIM Rules.
Additionally, the following directors and persons discharging managerial responsibilities, have conditionally participated in the Placing for, 15,714,291 Ordinary Shares at the Issue Price, raising gross proceeds of approximately £55,000.
| Director/PDMR | Number of Ordinary Shares held as at the date of this Announcement | Number of Placing Shares subscribed for in the Placing | Number of Ordinary Shares held on Admission | Percentage of issued ordinary share capital as enlarged by the Placing2 |
| Julian Baines | 5,691,338 | 2,857,144 | 8,548,482 | 0.4% |
| Sir Ian Carruthers | 2,100,000 | 2,857,144 | 4,957,144 | 0.2% |
| Sara Barrington | 4,000,000 | 4,285,715 | 8,285,715 | 0.4% |
| Lorenzo Gallon | 0 | 2,857,144 | 2,857,144 | 0.1% |
| David Anderson | 1,000,000 | 2,857,144 | 3,857,144 | 0.2% |
The independent Director, Aubrey Powell, having consulted with SCM Advisory as the Company’s nominated adviser, consider that the participation by Harwood Capital, Julian Baines, Sir Ian Carruthers, Sara Barrington Lorenzo Gallon, and David Anderson in the Placing are each fair and reasonable in so far as shareholders are concerned.
Notes
1 GBP:USD FX rate of £1:$1.32
2 This assumes the issue of the 700,000,000 Placing Shares only and does take into account any new issuance under the Retail Offer.
Total Voting Rights
A further announcement will be made in relation to total voting rights in the Company’s ordinary share capital following completion of the Retail Offer, when the total number of New Ordinary Shares to be issued pursuant to the Fundraising will be known.
